Reformulation-Focused Life Cycle Management of the FDA-Approved Drugs


Reformulation-Focused Life Cycle Management of the FDA-Approved Drugs

Journal of Health and Medical Research provides a global platform for facilitating and promoting health and medical research communications, exchange of research concepts, sharing of recent developments, observations, expert opinions and innovative concepts as well as coordinated scientific programs. With open accessibility, the journal aims to provide inspiration to the students, interns and young medical professionals in their research careers.

Scope of the Journal

Journal of Health and Medical Research publishes articles covering wide range of disciplines including Biochemistry, Pharmacology and Toxicology focused on developing effective medicines, efficient procedures dealing both preclinical aspects like molecular and cellular research, in vitro and animal model studies as well as clinical trials.

Health research topics relating to disease prevalence, risk factors, public health intervention outcomes as well as healthcare economics and medical research topics including etiology of disease, prognosis, management and treatment, functional aspects of human physiology, mechanisms of health improvement and reduction in the burden of disease are covered in this journal.

Drug Life Cycle Management (LCM) includes a variety of strategies that are implemented by biotech and pharmaceutical companies to uncover the hidden value of the drug and maximize their sales and extend their commercial lives.

Drug reformulation is one of the most widely used line extension strategies, which expands the therapeutic utility of drugs in different ways and provides market exclusivity. Reformulation allows pharmaceutical companies to address specific marketing needs, helps in strengthening a brand, repositioning a drug in an entirely new target population or even new therapeutic area or effectively treat patients with a specific clinical need.

The motivation for a company to reformulate its brand varies according to when the reformulation is implemented during the life cycle of the drug. In this review, we present and discuss the life cycle of two new molecular entities approved by the US Food and Drug Administration during the 2001-2010 decade, aripiprazole (Trade name, Abilify) and lacosamide (Trade name, Vimpat), highlighting the reformulation strategies adopted.

Journal of Health and Medical Research is glad to announce the 30% discount for the authors who submit their manuscript on or before April 20,2020.

Interested can submit their manuscript below:

Submit manuscript at or send as an e-mail attachment to the Editorial Office at

Media contact:

Maegan Smith

Managing Editor

Journal of Health and Medical Research

Mail ID:

WhatsApp no: + 1-504-608-2390